Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Revenue       $ 37
Operating expenses:        
Research and development $ (3,937) $ (28,066) $ (18,723) (69,892)
General and administrative (2,398) (2,933) (8,759) (8,988)
Total operating expenses (6,335) (30,999) (27,482) (78,880)
Operating loss (6,335) (30,999) (27,482) (78,843)
Interest expense, net (4,183) (216) (10,854) (455)
Financing transaction costs (685)   (2,815)  
Adjustments to fair value of derivatives (644)   1,023  
Other income, net 68 48 27 204
Total other expense (5,444) (168) (12,619) (251)
Loss before income taxes (11,779) (31,167) (40,101) (79,094)
Income tax expense (420) (104) (719) (395)
Net loss and comprehensive loss (12,199) (31,271) (40,820) (79,489)
Net loss attributable to ordinary shareholders $ (12,199) $ (31,271) $ (40,820) $ (79,489)
Net loss per share attributable to ordinary shareholders – basic and diluted $ (0.60) $ (2.15) $ (2.39) $ (5.52)
Weighted average ordinary shares outstanding – basic and diluted 20,392,357 14,571,278 17,078,326 14,412,755